ASRT
Assertio Holdings·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ASRT
Assertio Holdings, Inc.
A specialty pharmaceutical company that develops prescription drugs focused on pain and central nervus system conditions and diseases
100 South Saunders Road, Suite 300, Lake Forest, Illinois 60045
--
Assertio Holdings, Inc., is a leading diversified, commercial pharmaceutical company focused on providing unique products that enhance treatment options for patients in need. On May 19, 2020, Assertio implemented the Assertio Reorganization pursuant to the Merger Agreement and Plan. Assertio Therapeutics is a wholly-owned subsidiary of Assertio Holdings.
Earnings Call
Q2/2025
Estimate EPS-0.01
Actual EPS0.02
Estimate Revenue27.97M
Actual Revenue28.80M
Assertio Holdings Q2 2025: Examining Contradictions in Rolvedon and Sympazan Sales Dynamics
Aug 11,2025 07:56
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS0
Actual EPS-0.14
Estimate Revenue27.52M
Actual Revenue26.49M
Assertio's Q1 2025: Unraveling Contradictions in Strategy, Litigation Impact, and Rolvedon's Future
May 20,2025 07:36
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ASRT has released its 2025 Q2 earnings. EPS was reported at 0.02, versus the expected -0.01, beating expectations. The chart below visualizes how ASRT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ASRT has released its 2025 Q2 earnings report, with revenue of 29.22M, reflecting a YoY change of -6.12%, and net profit of -16.35M, showing a YoY change of -345.07%. The Sankey diagram below clearly presents ASRT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
